Company Overview and News
· The fumed silica market is projected to grow at a CAGR of 7.1% during the forecast period, in terms of value
Strong mainland trading debuts for clothes firm Annil and Shanghai Emperor of Cleaning Hi-Tech, both of which rise by 44pc limit. Cogobuy loses another 9pc
The report "Refrigerant Market by Type (HCFC, HFC, HFO, Isobutane, Propane, Ammonia, and CO2), Application (Refrigerators, Large-scale Refrigerators, Chillers, Air Conditioners, and Heat Pumps), Region - Global Forecast to 2022", published by MarketsandMarkets™, the global market was estimated at USD 14.49 Billion in 2017 and is projected to reach USD 18.05 Billion by 2022, at a CAGR of 4.5%.
The report "Heat Resistant Polymers Market by Type (Fluoropolymers, Polyimides, Polyphenylene Sulfide, PBI, Peek), End-Use Industry (Transportation, Electronics & Electrical), and Region - Global Forecast to 2021", published by MarketsandMarkets™, the market is projected to grow from USD 12.03 Billion in 2016 to USD 16.67 Billion by 2021, at a CAGR of 6.7% from 2016 to 2021.
LONDON, June 7, 2016 /PRNewswire/ -- The Global FEP coating market report defines and segments the concerned market with analysis and forecast of revenue. This market was valued at $114.9 million in 2014 and is expected to reach a value of $199.3 million by 2019 at a CAGR of 7.0% from 2014 and 2019. In 2014, the Asia-Pacific region dominated the global market for FEP coating with the largest market share of 36.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...